Biotech & AI drug discoverySTAT — Biotech

STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics reported that an experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer in a trial of the combo therapy. The figure is as reported by the company.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-23T10:30:00+00:00

Published here2026-10-23T11:02:41+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/

Original headline

STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.